Impaired Metabolism of High Density Lipoprotein in Uremic Patients
Overview
Authors
Affiliations
We measured lipoproteins, apolipoproteins, lipoprotein lipase (LPL), hepatic triglyceride lipase (HTGL), lecithin: cholesterol acyltransferase (LCAT) and parameters of calcium metabolism to evaluate the roles of these enzymes and hypertriglyceridemia for impaired high-density lipoprotein (HDL) metabolism in chronic renal failure, and to examine the impact of altered calcium homeostasis on the lipoprotein-regulating enzymes. The subjects were 25 healthy volunteers and 66 uremic patients, 24 treated with hemodialysis (HD) and 42 with continuous ambulatory peritoneal dialysis (CAPD). Lipoprotein analysis revealed: (1) reduction in HDL cholesterol especially in HDL2 subfraction; (2) increase in HDL triglyceride; and (3) decreased ratio of HDL2 cholesterol to HDL3 cholesterol in both HD and CAPD patients. Simple regression analysis showed: (1) a positive correlation between VLDL triglyceride and triglyceride/cholesterol ratio of HDL; (2) positive correlations of LPL level in post-heparin plasma to cholesterol concentrations in HDL2, HDL3 and total HDL, and to apolipoproteins A-I and A-II; and (3) inverse correlations of HTGL to HDL2 cholesterol and to the ratio of HDL2 cholesterol/HDL3 cholesterol. Multiple regression analysis of HDL cholesterol indicated positive association with LPL and inverse correlation with VLDL triglyceride. Four variables including LPL, HTGL, LCAT and VLDL triglyceride explained 51.5% of the variation of HDL cholesterol. HDL2 cholesterol was associated positively with LPL and negatively with VLDL triglyceride in the model. HDL3 cholesterol was associated positively with LPL, HTGL and LCAT and inversely with VLDL triglyceride. Stepwise multiple regression analysis indicated that independent predictors of HTGL were gender, parathyroid hormone levels by a mid-portion assay, ionized calcium and age, and that those of LCAT were ionized calcium and age.(ABSTRACT TRUNCATED AT 250 WORDS)
Statins Have an Anti-Inflammation in CKD Patients: A Meta-Analysis of Randomized Trials.
Wang J, Chen Z, Qiu Y, Wu L, Wang H, Wu L Biomed Res Int. 2022; 2022:4842699.
PMID: 36317110 PMC: 9617709. DOI: 10.1155/2022/4842699.
Cholesterol Disturbances and the Role of Proper Nutrition in CKD Patients.
Gluba-Brzozka A, Franczyk B, Rysz J Nutrients. 2019; 11(11).
PMID: 31752189 PMC: 6893650. DOI: 10.3390/nu11112820.
Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins.
Florens N, Calzada C, Lyasko E, Juillard L, Soulage C Toxins (Basel). 2016; 8(12).
PMID: 27999257 PMC: 5198570. DOI: 10.3390/toxins8120376.
HDL abnormalities in nephrotic syndrome and chronic kidney disease.
Vaziri N Nat Rev Nephrol. 2015; 12(1):37-47.
PMID: 26568191 DOI: 10.1038/nrneph.2015.180.
Gupta K, Mahajan R Int J Appl Basic Med Res. 2013; 1(1):11-4.
PMID: 23776765 PMC: 3657946. DOI: 10.4103/2229-516X.81973.